Miguel Widjaja

Analyst

Joining the investment team, Miguel supports in the diligence, execution and sourcing of iGan’s investments. Prior to joining iGan Partners, Miguel worked with early stage companies at Ryerson University’s start-up incubator program: the DMZ, where he helped in areas of business development, operations and fundraising. He was also a partner at enLight, a student run non-profit where he helped organize and run multiple conferences and hackathons focused on fostering entrepreneurship in universities across Canada.

Miguel graduated with an Honours Bachelor’s degree in Commerce specializing in Entrepreneurial Finance, from the Queen’s School of Business. He is a recipient of the Junior Achievement: Canadian Youth Leadership Award for his social entrepreneurial work in Chameleon Pencils, a non-profit which sent school supplies to underprivileged children around the world.

Trish Barbato

Clinical & Technical Advisory

SVP, Innovation at Revera

Trish Barbato provides strategic leadership for Revera in the area of innovation, one of the company’s core strategic priorities, and oversees the Information Technology function. She has deep experience in private, public and non-profit sectors of the health system, and served as Senior Vice President of Revera Home Health from 2010 to 2015. Before joining Revera in 2010, Ms. Barbato was President and CEO of COTA Health (mental health and rehabilitation services). She was Vice President, Corporate Services and Chief Financial Officer of Providence Healthcare, and Managing Director of Bayshore Healthcare. Ms. Barbato defines success as exceeding resident expectations, keeping employees deeply engaged and being open to new ideas. She’s a Chartered Professional Accountant Fellow, holds an Economics degree from the University of Waterloo and a Queen’s Diamond Jubilee award recipient.

Sachin Aggarwal

Clinical & Technical Advisory

CEO, Think Research

Sachin is the Chief Executive Officer of Think Research, Sachin Aggarwal understands that health care systems around the world are on the brink of profound, necessary change. Scientific knowledge, clinical best practices and medical data are increasing at an exponential rate, contributing to a global knowledge crisis – with implications for clinicians, patients, governments and countries at large.

In the midst of this growing problem, Sachin sees data as the solution – and the key to system transformation. This principle drives the mission of Think Research: to organize the world’s health knowledge so that everyone gets the best care.

As part of this vision, Sachin led Think Research in 2010 through a strategic transition to become a cloud-based service provider. The move has positioned Think Research as a leader in the global health data economy, allowing the company to standardize care at scale, aggregate knowledge across health systems and improve the quality of care for patients.

When he’s not advocating for disruptive change in health care, Sachin is actively engaged in his community. A recipient of Canada’s Top 40 Under 40 Award in 2017, Sachin also sits on the Board of the Council of Canadian Innovators. He previously served as the Deputy Chief of Staff for the Office of the Leader of the Opposition prior to joining Think Research. He’s currently a Senior Fellow in Public Policy at the Munk School of Global Affairs and Public Policy, and has served as an advisor to numerous start-up and scale-up companies in the innovation sector. He was called to the Bar in Ontario and New York, and holds an MBA from the Rotman School of Management.

Mike Stein

Clinical & Technical Advisory

Former CEO, CAPREIT

Mr. Stein is the founder, Chairman and CEO of the MPI Group, a property development and investment group with a track record in incubating, investing in, and managing successful companies. Between 1978 and 1987, Mr. Stein held progressively senior positions with the Mortgage Insurance Company of Canada, ultimately holding the position of Executive Vice-President responsible for operations. Mr. Stein is the founding CEO and Chairman of CAPREIT, Canada’s first TSX listed apartment REIT, where he continues to serve as Chairman. He currently serves as a director of First Service Corporation (TSX), chairman of Cliffside Capital Ltd. (TSX-V) and previously served as a director of CSA Management and Goldcorp Inc.

Mr. Stein is a graduate engineer and has an MBA in finance and international business from Columbia University.

Dr. Andrew Padmos

Clinical & Technical Advisory

CEO, the royal college of physicians and surgeons in Canada

Andrew Padmos, BA, MD, FRCPC, FACP, FRCP joined the Royal College as the new CEO on September 1, 2006. He comes to the Royal College from Halifax, N.S., where from 1998 he was commissioner of Cancer Care Nova Scotia, head of the Cancer Care Program at the QEII Health Sciences Centre, associate dean for cancer programs in the Faculty of Medicine at Dalhousie University and vice-president of research, academic affairs and quality for Capital District Health Authority. Prior to working for Cancer Care Nova Scotia, Dr. Padmos was the director and CEO of the Kingston Regional Cancer Centre in Kingston, Ont., and professor and head of oncology at Queen’s University, Kingston General and Hotel Dieu hospitals.

Educated in political science and economics at the University of Toronto and in medicine at McMaster University, Dr. Padmos completed specialty training in internal medicine and hematology and was certified by the Royal College in 1976. A hematologist by profession, Dr. Padmos practised medicine in Calgary, Alta., for two years before a 15-year term at King Faisal Specialist Hospital and Research Centre in Riyadh, Saudi Arabia. During this time, he introduced a bone marrow transplant program, developed a large clinical program in hematology/oncology and served in many administrative capacities.

Dr. Frank Prendergast

Clinical & Technical Advisory

President, Wodlinger Consulting

Franklyn G. Prendergast, M.D., Ph.D., is a consultant in the Department of Molecular Pharmacology and Experimental Therapeutics and the Department of Biochemistry and Molecular Biology at Mayo Clinic in Rochester. He holds the academic rank of professor of biochemistry, molecular biology and pharmacology. In addition, he is recognized with the distinction of a named professorship, the Edmond and Marion Guggenheim Professorship of Biochemistry and Molecular Biology. He served as director of Mayo Clinic Cancer Center from 1994 to 2006 and currently is director of the Mayo Clinic Center for Individualized Medicine.

Dr. Prendergast obtained his medical degree with honors from the University of West Indies and attended Oxford University as a Rhodes Scholar, earning the M.A. degree in physiology. After an internal medicine residency at Mayo Clinic, Dr. Prendergast obtained the Ph.D. degree in biochemistry at the University of Minnesota/Mayo Graduate School.

Dr. Prendergast is the former chair of the Department of Biochemistry and Molecular Biology and the former director for research at Mayo Clinic in Rochester from 1989-1992. From 1989-1996, inclusive, he was a member of the Board of Governors for Mayo Clinic in Rochester. He has served on Mayo Clinic Board of Trustees continuously between 1992-2009 also has served on Mayo Clinic’s Board of Governors, the senior governance committee responsible for governance of the entire institution. He was recognized as a Mayo Distinguished Investigator in 1988.

Extramurally, Dr. Prendergast has served extensively for the National Institutes of Health (NIH) on numerous study section review groups; as a charter member of the Board of Advisors for the Division of Research Grants, now the Center for Scientific Review; the National Advisory General Medical Sciences Council; the Board of Scientific Advisors of the National Cancer Institute. He held a Presidential Commission for service on the National Cancer Advisory Board. Dr. Prendergast also has served in numerous other advisory roles for the NIH and the National Research Council of the National Academy of Sciences, and he is a member of the board of directors of the Translational Genomics Research Institute and the Infectious Disease Research Institute (IDRI).

Mike Aron

CO-founder & director, cidel bank & trust

Michael has over 20 years of experience in corporate finance, investment banking and entrepreneurship. He is a Co-Founder and Director of Cidel Bank & Trust, an international private bank, and the Co-Founder of several hedge fund families. Prior to founding Cidel, Michael was a Senior Executive at Bayshore Bank and a Senior Manager at KPMG Peat Marwick’s financial advisory practice. Michael Aron has been involved as a primary investor and founder in a wide variety of businesses in industries including life sciences, financial, consumer services, real estate, resources and banking.

Dr. Stuart Foster

Clinical & Technical Advisory

Senior Scientist, Sunnybrook

Stuart Foster is currently a senior scientist at Sunnybrook Research Institute and Professor and Canada Research Chair in Ultrasound Imaging, Department of Medical Biophysics, University of Toronto. His current research centres on the development of high frequency clinical and preclinical imaging systems, array technology, intravascular imaging, photoacoustics, and molecular imaging. Stuart is a Fellow of the American Institute of Ultrasound in Medicine and IEEE. He is the founder and former Chairman of VisualSonics Inc., a company dedicated to preclinical imaging. Dr. Foster co-founded the Mouse Imaging Centre (MICe) now at the Toronto Centre for Phenogenomics. He has served on the Board of Directors of the National Cancer Institute of Canada and as Chairman of its Committee on Research (ACOR). He has previously been the recipient of the Eadie Medal for major contributions to engineering in Canada, the Queen’s Golden Jubilee Medal, the Manning Award of Distinction for Canadian Innovation, the Ontario Premier’s Discovery Award, and the Rayleigh Award from IEEE. He serves on numerous advisory bodies and is currently on the editorial boards of Ultrasonic Imaging and Ultrasound in Medicine and Biology.

Dr. Ralph DaCosta

Clinical & Technical Advisory

Founder & CSO, MolecuLight

Dr. Ralph DaCosta received his PhD from the Department of Medical Biophysics, University of Toronto. His graduate research focused on the development and pioneering clinical application of advanced optical molecular imaging technologies for endoscopic diagnosis of early gastrointestinal cancers.

This work contributed to major improvements in the accuracy of conventional diagnostic endoscopy. These continue to directly benefit endoscopic cancer screening strategies around the world. Dr. DaCosta is a Scientist, Princess Margaret Cancer Centre, University Health Network (UHN). He is developing a comprehensive research program at UHN that focuses on accelerating the translation of these “bioimaging” capabilities directly into clinical practice. He also is a member of the Radiation Medicine Program (Princess Margaret Cancer Centre) and the Spatio-Temporal Targeted and Amplification of Radiation Response (STTARR) Innovation Center at UHN.

Dr. DaCosta is one of Canada’s leading experts in the area of biophotonics. His ongoing contribution to the field of cancer imaging has been recognized by numerous awards and invited presentations at international meeting

Dr. Matthew Benjamin

Clinical & Technical Advisory

Partner, EXR Medical

Dr. Benjamin has been a partner of EXR Medical Imaging since 2005. Dr. Benjamin trained in Diagnostic Radiology at Massachusetts General Hospital in Boston where he completed a fellowship in Vascular and Interventional Radiology. Prior to joining EXR, he was on staff at the University Health Network, and was an Assistant Professor at the University of Toronto. Dr Benjamin’s practice includes all diagnostic and interventional radiology with special interest in MRI and mammography.